Back to Search Start Over

To explore the mechanism of gypenosides in the treatment of liver injury in rats based on GC-MS metabolomics and bile acid metabolism pathway.

Authors :
Zhang Z
Yue R
Wang Y
Ma L
Wang M
Chen Y
Source :
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2025 Jan 01; Vol. 252, pp. 116506. Date of Electronic Publication: 2024 Oct 09.
Publication Year :
2025

Abstract

Gynostemma pentaphyllum is a herbaceous vine of Cucurbitaceae family, and its principal pharmacological components, gypenosides (GPs), have been proved to be effective in various liver diseases. However, the mechanisms of GPs on liver injury are still to be studied for further. This investigation utilized the CCl <subscript>4</subscript> -induced liver injury rat model (LI) to comprehensively explore the mechanism of action of GPs in the treatment of chemical liver injury by comparing the metabolomic changes in four groups rats. In this study, the therapeutic efficacy of GPs in a liver injury rat model induced by weekly gavage of CCl <subscript>4</subscript> was evaluated by inflammatory factors, oxidative damage indexes, and histopathological sections. Then, GC-MS technology was used to identify the metabolic profile of GPs in treating liver injury. Finally, the content variation of metabolites (BAs and SCFAs) was measured to elucidate the mechanism of GPs in the treatment of CCl <subscript>4</subscript> -induced liver injury. After 8 weeks of administration, GPs effectively reduced the degree of LI and appeared a substantial tendency of reversing in the levels of MDA, GSH, CYP7E1, CYP7A1 and CYP27A1. Untargeted metabolomics suggested that GPs may play a role in BAs and SCFAs metabolism. Targeted metabolomics and ELISA confirmed the key role of GPs in increasing SCFAs levels and regulating BAs metabolism. Overall, this study indicated that GPs can alleviate CCl <subscript>4</subscript> -induced liver injury. And GPs may exert beneficial effects on LI by affecting their metabolites (SCFAs and BAs).<br />Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Miao Wang reports financial support was provided by Shenyang Pharmaceutical University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-264X
Volume :
252
Database :
MEDLINE
Journal :
Journal of pharmaceutical and biomedical analysis
Publication Type :
Academic Journal
Accession number :
39418697
Full Text :
https://doi.org/10.1016/j.jpba.2024.116506